Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 睿昂基因（上证代码：688217）成立于2012年，专注于为肿瘤精准医疗提供具有临床价值的肿瘤精准分型、MRD监测、肿瘤早筛检测的诊断产品与服务，让更多人免受肿瘤伤害。 1）基于7大技术平台（荧光定量PCR平台、一代测序平台、二代测序（NGS）平台、数字PCR平台、FISH平台、多色流式平台、Nanosting平台）的血液肿瘤患病人群检测，每年超过20万例检测数据，积累了庞大的血液肿瘤检测数据库； 2）基于3大技术（数字PCR、二代测序（NGS）、全光谱流式）的实体肿瘤患病人群检测，目前已经完成液体活检创新技术平台搭建； 3）基于液体活检技术的肿瘤早筛检测服务。
Main Business 体外诊断产品（包括检测仪器及检测试剂）的研发、生产、销售及科研、检测服务
Legal Representative 高尚先
Top Executives
董事长：熊慧
董事长(代)：高尚先
董事：程良英,孙彦波,高泽,熊钧,高尚先
独立董事：赵贵英,姜广策,袁学伟
Top 5 Shareholder
Shareholder name Nature Holding Date
熊慧流通A股18.22%30/09/2024
杭州迪通创健股权投资基金管理有限公司－浙江大健康产业股权投资基金（有限合伙）流通A股10.10%30/09/2024
宁波伯慈创业投资合伙企业（有限合伙）流通A股8.82%30/09/2024
上海力漾投资合伙企业（有限合伙）流通A股3.58%30/09/2024
徐博流通A股3.36%30/09/2024
Company Secretary 李彦
Solicitors 上海市锦天城律师事务所
Auditors 中汇会计师事务所（特殊普通合伙）
Tel No 021-33282601
Fax No 021-37199015
Website www.rightongene.com
Email zqswb@rightongene.com
Company Address
Register: 上海市奉贤区金海公路6055号3幢
Office: 上海市奉贤区汇丰西路1817弄147号
Listing Date 17/05/2021
Shares Capital
Shares Capital: 55,855,896
Total A Share: 55,855,896
Listed A Share: 55,855,896
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.140
DPS(RMB)* ¥ 0.180
NBV Per Share(RMB)* ¥ 16.932
Market Capitalization(RMB) 1.205B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.